Bristol claims victory in crucial immunotherapy trial, but results raise some questions – STAT
STAT |
Bristol claims victory in crucial immunotherapy trial, but results raise some questions
STAT ristol-Myers Squibb reported positive results Monday in a crucial immunotherapy trial, using a combination of the two drugs Opdivo and Yervoy to treat patients with a specific type of non-small cell lung cancer patients. The outcome of the study known … Bristol-Myers says a key trial for its lung cancer drug succeeds Bristol-Myers' lung cancer drug succeeds key trial; shares rise UPDATED: Bristol-Myers scores big, wows checkpoint field with an early hit on Opdivo-Yervoy combo for lung cancer |
